Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × infigratinib × Genitourinary × Clear all

Phase

Status

Terminated 2 Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Urinary Bladder Neoplasms 1 Acrocephalosyndactylia 1

Interventions

pembrolizumab 16 Docetaxel 15 Prednisone 13 Magnetic Resonance Spectroscopy 12 Radiotherapy 11 bicalutamide 9 Leuprolide 9 Cyclophosphamide 8 Biopsy 8 avelumab 7 Radiosurgery 7 Abiraterone Acetate 7 atezolizumab 6 Specimen Handling 6 Interleukin-2 6 tremelimumab 5 gallium 68 PSMA-11 5 apalutamide 5 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5 Paclitaxel 5 Metformin 5 Gemcitabine 5 Bevacizumab 5 Androgen Antagonists 5 radium Ra 223 dichloride 4 enzalutamide 4 durvalumab 4 cabazitaxel 4 Sunitinib 4 Sorafenib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn

Acrocephalosyndactylia, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡